February 25, 2019 / 11:46 AM / 5 months ago

BRIEF-Akcea Therapeutics Says Co Will Receive A $150 Mln License Fee That Will Be Split Equally With Ionis

Feb 25 (Reuters) - Akcea Therapeutics Inc:

* AKCEA-APO(A)-LRX ADVANCES AS LEADING PHARMACEUTICAL COMPANY EXERCISES OPTION TO LICENSE

* AKCEA THERAPEUTICS INC - AKCEA WILL RECEIVE A $150 MILLION LICENSE FEE THAT WILL BE SPLIT EQUALLY WITH IONIS

* AKCEA THERAPEUTICS INC - PHASE 3 PLANNING AND INITIATION ACTIVITIES UNDERWAY

* AKCEA THERAPEUTICS INC - NOVARTIS HAS EXERCISED ITS OPTION TO LICENSE AKCEA-APO(A)-LRX

* AKCEA THERAPEUTICS INC - NOVARTIS TO ASSUME RESPONSIBILITY FOR ALL FUTURE DEVELOPMENT ACTIVITIES FOR AKCEA-APO(A)-LRX

* AKCEA THERAPEUTICS INC - AKCEA WILL SETTLE ITS $75 MILLION OBLIGATION TO IONIS IN AKCEA COMMON STOCK. Source text: (bit.ly/2EuMiRk) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below